Literature DB >> 19165723

Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn.

Hai Pan1, Kenneth Chen, Liping Chu, Francis Kinderman, Izydor Apostol, Gang Huang.   

Abstract

Susceptibility of methionine residues to oxidation is a significant issue of protein therapeutics. Methionine oxidation may limit the product's clinical efficacy or stability. We have studied kinetics of methionine oxidation in the Fc portion of the human IgG2 and its impact on the interaction with FcRn and Protein A. Our results confirm previously published observations for IgG1 that two analogous solvent-exposed methionine residues in IgG2, Met 252 and Met 428, oxidize more readily than the other methionine residue, Met 358, which is buried inside the Fc. Met 397, which is not present in IgG1 but in IgG2, oxidizes at similar rate as Met 358. Oxidation of two labile methionines, Met 252 and Met 428, weakens the binding of the intact antibody with Protein A and FcRn, two natural protein binding partners. Both of these binding partners share the same binding site on the Fc. Additionally, our results shows that Protein A may serve as a convenient and inexpensive surrogate for FcRn binding measurements.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19165723      PMCID: PMC2708056          DOI: 10.1002/pro.45

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  52 in total

1.  Oxidation of a critical methionine modulates DNA binding of the Drosophila melanogaster high mobility group protein, HMG-D.

Authors:  L K Dow; A Changela; H E Hefner; M E Churchill
Journal:  FEBS Lett       Date:  1997-09-15       Impact factor: 4.124

2.  Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2.

Authors:  X M Lam; J Y Yang; J L Cleland
Journal:  J Pharm Sci       Date:  1997-11       Impact factor: 3.534

3.  Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn.

Authors:  E J Israel; D F Wilsker; K C Hayes; D Schoenfeld; N E Simister
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

4.  Oxidation of methionine residues of recombinant human interleukin 2 in aqueous solutions.

Authors:  K Sasaoki; T Hiroshima; S Kusumoto; K Nishi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1989-08       Impact factor: 1.645

5.  Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction.

Authors:  A L Corper; M K Sohi; V R Bonagura; M Steinitz; R Jefferis; A Feinstein; D Beale; M J Taussig; B J Sutton
Journal:  Nat Struct Biol       Date:  1997-05

6.  Crystal structure of the complex of rat neonatal Fc receptor with Fc.

Authors:  W P Burmeister; A H Huber; P J Bjorkman
Journal:  Nature       Date:  1994-11-24       Impact factor: 49.962

7.  Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G.

Authors:  Georgeen Gaza-Bulseco; Sagar Faldu; Karen Hurkmans; Chris Chumsae; Hongcheng Liu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-06-05       Impact factor: 3.205

8.  13C NMR study of the mode of interaction in solution of the B fragment of staphylococcal protein A and the Fc fragments of mouse immunoglobulin G.

Authors:  K Kato; H Gouda; W Takaha; A Yoshino; C Matsunaga; Y Arata
Journal:  FEBS Lett       Date:  1993-08-09       Impact factor: 4.124

9.  Regulation of oxidative degradation of L-lysine in rat liver mitochondria.

Authors:  P W Scislowski; A R Foster; M F Fuller
Journal:  Biochem J       Date:  1994-06-15       Impact factor: 3.857

10.  Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG.

Authors:  A E Sauer-Eriksson; G J Kleywegt; M Uhlén; T A Jones
Journal:  Structure       Date:  1995-03-15       Impact factor: 5.006

View more
  48 in total

Review 1.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

2.  Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.

Authors:  Tilman Schlothauer; Petra Rueger; Jan Olaf Stracke; Hubert Hertenberger; Felix Fingas; Lothar Kling; Thomas Emrich; Georg Drabner; Stefan Seeber; Johannes Auer; Stefan Koch; Apollon Papadimitriou
Journal:  MAbs       Date:  2013-05-29       Impact factor: 5.857

Review 3.  Oxidation of therapeutic proteins and peptides: structural and biological consequences.

Authors:  Riccardo Torosantucci; Christian Schöneich; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

4.  Chemical modifications in therapeutic protein aggregates generated under different stress conditions.

Authors:  Quanzhou Luo; Marisa K Joubert; Riki Stevenson; Randal R Ketchem; Linda O Narhi; Jette Wypych
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 5.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

Review 6.  Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration.

Authors:  Ninad Varkhede; Rupesh Bommana; Christian Schöneich; M Laird Forrest
Journal:  J Pharm Sci       Date:  2019-08-10       Impact factor: 3.534

Review 7.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

8.  Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodies.

Authors:  Rong Yang; Tushar Jain; Heather Lynaugh; R Paul Nobrega; Xiaojun Lu; Todd Boland; Irina Burnina; Tingwan Sun; Isabelle Caffry; Michael Brown; Xiaoyong Zhi; Asparouh Lilov; Yingda Xu
Journal:  MAbs       Date:  2017-02-14       Impact factor: 5.857

9.  Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.

Authors:  Yanli Zhuang; Di Chen; Amarnath Sharma; Zhenhua Xu
Journal:  AAPS J       Date:  2018-10-15       Impact factor: 4.009

Review 10.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.